Loading patent…
AssigneeYale University
InventorsMargarita Dominguez-Villar, David A. Hafler
Estimating the term…
The present invention includes compositions and methods of inhibiting or activating TLR7 signaling. In one aspect, a composition includes an inhibitor of TLR7 signaling is described, where the inhibitor of TLR7 signaling is a TLR7 inhibitory oligonucleotide, a TLR7 antibody, or a TLR7 antagonist. In another aspect, a composition and method are described for preventing and treating viral infection of a T cell in a subject. Methods for decreasing T cell proliferation by administering a composition with a TLR7 ligand or agonist or inducing T cell anergy in a subject by stimulating T cells with a TLR7 ligand or agonist are also described.
A method of preventing a viral infection of a T cell in a subject in need thereof comprising administering a composition comprising an inhibitor of TLR7 signaling selected from the group consisting of dual-iODN, IMO-3100, DV056, DV1179, chloroquine, hydroxychloroquine, quinacrine, and any combination thereof and further comprising administering a CD3 antibody, an ICOS antibody, or a CD28 antibody to the subject, wherein viral infection of the T cell is prevented following administration of the composition.
A method of treating a viral infection in a subject in need thereof comprising administering a composition comprising an inhibitor of TLR7 signaling to the subject, wherein the viral infection is reduced in the subject following administration of the TLR7 inhibitor.
Dependencies are inferred from the claim text.